A

Atossa Therapeutics
D

ATOS

0.83300
USD
-0.04
(-4.45%)
مغلق
حجم التداول
12,308
الربح لكل سهم
-0
العائد الربحي
-
P/E
-4
حجم السوق
107,598,613
أصول ذات صلة
A
AVXL
-0.16500
(-2.15%)
7.51000 USD
B
BKYI
-0.04910
(-5.84%)
0.79100 USD
D
DVAX
-0.02000
(-0.20%)
9.79500 USD
G
GNPX
0.01070
(4.04%)
0.27570 USD
I
IBIO
-0.00110
(-0.14%)
0.80700 USD
I
INO
-0.06000
(-2.98%)
1.95500 USD
N
NVAX
-0.04000
(-0.55%)
7.25000 USD
V
VXRT
-0.00260
(-0.56%)
0.46340 USD
المزيد
الأخبار المقالات

العنوان: Atossa Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.